Zobrazeno 1 - 10
of 1 165
pro vyhledávání: '"S, Sulkowski"'
Autor:
Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T. Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G. Nahass, James S. Park, Ira M. Jacobson, Walid S. Ayoub, Steven-Huy Han, Edward J. Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T. Dieterich, Paul Yien Kwo, Eugene R. Schiff, Ho S. Bae, Jacob Lalezari, Kosh Agarwal, Mark S. Sulkowski
Publikováno v:
JHEP Reports, Vol 6, Iss 4, Pp 100999- (2024)
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In this long-term extension study, patie
Externí odkaz:
https://doaj.org/article/79c1f480374a43d2b19433829b3f31b0
Autor:
Tanner Grudda, Hyon S. Hwang, Maraake Taddese, Jeffrey Quinn, Mark S. Sulkowski, Richard K. Sterling, Ashwin Balagopal, Chloe L. Thio
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 18 (2022)
The focus of hepatitis B functional cure, defined as sustained loss of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA from blood, is on eliminating or silencing the intranuclear template for HBV replication, covalently closed circular DN
Externí odkaz:
https://doaj.org/article/4ae31255e99b4eb3a92cbb60ecbdf52f
Autor:
David E. Bernstein, Albert Tran, Paul Martin, Kris V. Kowdley, Marc Bourliere, Mark S. Sulkowski, Paul J. Pockros, Boris Renjifo, Deli Wang, Diana L. Shuster, Daniel E. Cohen, Ira M. Jacobson
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 245-256 (2019)
Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods: We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1–infected
Externí odkaz:
https://doaj.org/article/fee2a1ab44074b91b2b9751f3f900276
Autor:
Saleh A. Alqahtani, Mark S. Sulkowski
Publikováno v:
Medical Clinics of North America. 107:423-433
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5e5a078fc76d6869c13afbafe19a60b
https://doi.org/10.1016/j.mcna.2023.01.001
https://doi.org/10.1016/j.mcna.2023.01.001
Autor:
Mark S. Sulkowski
Publikováno v:
Journal of Viral Hepatitis. 30:40-43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b14b175525e4a4551ebeafced97511da
https://doi.org/10.1111/jvh.13825
https://doi.org/10.1111/jvh.13825
Autor:
Ashwin Balagopal, Tanner Grudda, Ruy M. Ribeiro, Yasmeen S. Saad, Hyon S. Hwang, Jeffrey Quinn, Michael Murphy, Kathleen Ward, Richard K. Sterling, Yang Zhang, Alan S. Perelson, Mark S. Sulkowski, William O. Osburn, Chloe L. Thio
Publikováno v:
JCI Insight, Vol 5, Iss 19 (2020)
There is no cure for the more than 270 million people chronically infected with HBV. Nucleos(t)ide analogs (NUCs), the mainstay of anti-HBV treatment, block HBV reverse transcription. NUCs do not eliminate the intranuclear covalently closed circular
Externí odkaz:
https://doaj.org/article/136740c7fc1d43fba073ba9d5632fde6
Autor:
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T. Nguyen, Eugene R. Schiff, Hie-Won L. Hann, Douglas T. Dieterich, Ronald G. Nahass, James S. Park, Sing Chan, Steven-Huy B. Han, Edward J. Gane, Michael Bennett, Katia Alves, Marc Evanchik, Ran Yan, Qi Huang, Uri Lopatin, Richard Colonno, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Ira M. Jacobson, Walid S. Ayoub, Frank Weilert, Natarajan Ravendhran, Alnoor Ramji, Paul Yien Kwo, Magdy Elkhashab, Tarek Hassanein, Ho S. Bae, Jacob P. Lalezari, Scott K. Fung, Mark S. Sulkowski
Publikováno v:
Journal of Hepatology. 77:642-652
HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd7a77f9cac5a69525b2790e5ecdf2d1
https://doi.org/10.1016/j.jhep.2022.04.005
https://doi.org/10.1016/j.jhep.2022.04.005
Autor:
Chloe L Thio, Maraake Taddese, Yasmeen Saad, Kristina Zambo, Ruy M Ribeiro, Tanner Grudda, Mark S Sulkowski, Richard K Sterling, Yang Zhang, Eric D Young, Hyon S Hwang, Ashwin Balagopal
Publikováno v:
The Journal of Infectious Diseases.
Background Nucleos(t)ide analogues (NUCs) rarely cure chronic hepatitis B (CHB) because they do not eliminate covalently closed circular deoxyribonucleic acid, the stable replication template. In hepatitis B e antigen (HBeAg)-positive CHB during NUCs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecae9799d15b2a5ada7efe0e4e3ba9c3
https://doi.org/10.1093/infdis/jiad124
https://doi.org/10.1093/infdis/jiad124
Autor:
Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 333-349 (2016)
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naï
Externí odkaz:
https://doaj.org/article/dda945401c9c4406bf45486119425e6e
Autor:
Jaiprasath Sachithanandham, Ashwin Balagopal, Julia Leep-Lazar, Jeffrey Quinn, Kenneth Bowden, Kathleen Ward, Ruy M Ribeiro, Mark S Sulkowski
Publikováno v:
The Journal of Infectious Diseases.
BackgroundMathematical models explain how antivirals control viral infections. Hepatitis C virus (HCV) treatment results in at least 2 phases of decline in viremia. The first phase reflects clearance of rapidly produced virions. The second phase is h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86a57bf29d5617073fa70bcb7b0101e6
https://doi.org/10.1093/infdis/jiad025
https://doi.org/10.1093/infdis/jiad025